Related Experiment Video

Updated: Aug 17, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Hypothyroidism predicts worsened prognosis in patients undergoing percutaneous coronary intervention

Ben Cohen1,2, Tamir Bental1,2, Liat Perl2,3

  • 1Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel.

Frontiers in Cardiovascular Medicine
|December 16, 2022
PubMed

Insights

Hypothyroidism significantly increases mortality and major adverse cardiac events (MACE) in patients undergoing percutaneous coronary intervention (PCI). Further research is needed to mitigate this heightened risk in cardiovascular disease patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Thyroid dysfunction is linked to cardiovascular disease, with hypothyroidism associated with dyslipidemia, atherosclerosis, and heart failure.
  • The impact of hypothyroidism on patients undergoing percutaneous coronary intervention (PCI) remains under-researched.

Purpose of the Study:

  • To investigate the effect of hypothyroidism on mortality and major adverse cardiac events (MACE) in patients who have undergone PCI.

Main Methods:

  • Analysis of the Rabin Medical Center PCI registry (2004-2020) including 28,274 patients.
  • Comparison of mortality and MACE rates between patients with and without hypothyroidism.
  • Propensity score matching and multivariate analysis to assess outcomes.

Main Results:

  • Hypothyroid patients (6.8% of cohort) were older, more likely female, and had higher rates of comorbidities.
  • Unadjusted 5-year mortality (26.9% vs. 20.3%) and MACE (40.3% vs. 29.4%) were higher in hypothyroid patients.
  • Multivariate analysis showed TSH levels positively correlated with increased mortality and MACE risk.

Conclusions:

  • Hypothyroidism is associated with worse outcomes, including higher mortality and MACE, in patients undergoing PCI.
  • Elevated TSH levels indicate an augmented risk for adverse cardiovascular events post-PCI.
  • Further studies are required to develop strategies for managing this increased risk.
Abstract

Keywords:
hypothyroidischemic heart diseasemajor cardiovascular adverse eventoutcomespercutaneous coronary intervention (PCI)

More Related Videos

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.1K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
112
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
27
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
22
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
31